Gene therapy clinical trials worldwide to 2007 - An update

Journal of Gene Medicine

Volumn 9, Issue 10, 2007, Pages 833-842

  Edelstein, Michael L ^a   Abedi, Mohammad R ^b   Wixon, Jo ^c  

^a Hemel Hempstead General Hospital   (United Kingdom)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c John Wiley & Sons Inc United Kingdom   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CERE 120; GENDICINE; GENE THERAPY AGENT; GLUTAMATE DECARBOXYLASE; NEURTURIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANGIOGENIC GENE THERAPY; CANCER; CANCER GENE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DATA BASE; DRUG SCREENING; EYE DISEASE; FATALITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION; INFORMATION PROCESSING; MEDICAL RESEARCH; MONOGENIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; TREATMENT INDICATION; VIRAL GENE THERAPY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC DISEASES, INBORN; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 35148817461     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1100     Document Type: Review

References (43)

1. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med 2004; 6: 597-602.
2. Rosenberg SA, Aebersold P, Cornetta. K, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570-578.
3. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
4. Couzin J, Kaiser J. As Gelsinger case ends, gene therapy suffers another blow. Science 2005; 307: 1028.
5. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
7. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
8. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
9. Ginn SL, Curtin JA, Kramer B, et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Aust 2005; 182: 458-463.
10. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006; 14: 505-513.
11. Gansbacher B for the European Society of Gene Therapy. Policy statement on the social, ethical and public awareness issues in gene therapy. J Gene Med 2002; 4: 687-691.
12. Gansbacher B for the European Society of Gene Therapy. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT). J Gene Med 2003; 5: 261-262.
13. Report from the ASGT Ad Hoc Committee on Retroviral-mediated Gene Transfer to Hematopoietic Stem Cells. Available: http://www.asgt.org/ position§atements/report_042003/index.html.
14. Check E. Harmful potential of viral vectors fuels doubts over gene therapy. Nature 2003; 423: 573-574.
15. Kohn DB, Gansbacher B. Letter to the editors of Nature from the American Society of Gene Therapy (ASGT) and the European Society of Gene Therapy (ESGT). J Gene Med 2003; 5: 641.
16. Gene Therapy Advisory Committee 12th Annual Report (pages 10 and 13-15). Available: http://www.advisorybodies.doh.gov.uk/genetics/gtac/ GTAC12thannualReport.pdf.
17. Buchholz CJ, Cichutek K. Is it going to be SIN? J Gene Med 2006; 8: 1274-1276.
18. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
19. European Society of Gene Therapy (ESGT). One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease: A position statement from the European Society of Gene Therapy (ESGT). J Gene Med 2006; 8: 1435.
20. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
21. Rush University Medical Center and UCSF researchers found gene therapy appeared to reduce symptoms of Parkinson's disease by 40 percent. Press release from Rush University Medical Center, October 16, 2006; Available: http://www.rush.edu/webapps/MEDREL/servlet/NewsRelease?id=802.
22. During MJ, Feigin A, Eidelberg D, et al. Subthalamic GAD gene transfer improves brain metabolism associated with clinical recovery in Parkinson's disease. Abstracts from Neuroscience 2006: The 36th Annual Meeting of the Society for Neuroscience; No. 510.9. Available: http://www.sfn.org/index.cfm?pagename= abstracts_ampublications§ion=publications.
23. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-10127.
24. Guo G, Xin H. Chinese gene therapy: splicing out the west? Science 2006; 314: 1232-1235.
25. NIH Recombinant DNA Advisory Committee (RAC). Available: http://www4.od.nih.gov/oba/rac/aboutrdagt.htm.
26. UK Department of Health: Gene Therapy Advisory Committee (GTAC). Available: http://www.doh.gov.uk/genetics/gtac/.
27. Belgian Biosafety Server gene therapy clinical trials information. Available: http://www.biosafety.be/GT/regulatory/GTtrials.html.
28. DeReG - German Somatic Gene Transfer Clinical Trial Database. Available: http://www.zks.uni-freiburg.de/dereg/index_engl.html.
29. Gene Therapy Research Advisory Panel (GTRAP) of Australia. Available: http://www.health.gov.au/nhmrc/research/gtrap.htm.
30. Swiss Expert Committee for Biosafety (EFBS/CFSB) gene therapy clinical trials information. Available: http://www.efbs.ch/buwal/eng/fachgebiete/ fg_efbs/rubrik_gentherapie/gen_versuche/index.html.
31. Chinese State Food and Drug Administration clinical trials database. Available: http://appl.sfda.gov.cn/webportal/ portal.po?UID=DWV1_WOUID_URL_4258.
32. Dutch Ministry of Housing, Spatial Planning and the Environment (VROM) GGO Office site. Available: http://www.vrom.nl/ggo-vergunningverlening.
33. European Community clinical trials database (EudraCT). Available: http://eudract.emea.europa.eu/.
34. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
35. Laufs S, Nagy KZ, Giordano FA, Hotz-Wagenblatt A, Zeller WJ, Fruehauf S. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 2004; 10: 874-881.
36. Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
37. Reynolds A, Anderson E, Vermeulen A, et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006; 12: 988-993.
38. Sirna Therapeutics announces programs in strategic research alliance with GlaxoSmithKline. Press release from Sirna Therapeutics. Available: http://phx.corporate-ir.net/phoenix.zhtml?c=141787&p= irol-newsArticle&ID=852037&highlight=.
39. Merck & Co., Inc. announces completion of acquisition of Sirna Therapeutics, Inc. Press release from Sirna Therapeutics. Available: http://phx.corporate-ir.net/phoenix.zhtml?c=141787&p= irol-newsArticle&ID=945592&highlight=.
40. Mirus Bio awarded broad European patent covering intravascular injection method. Press release from Mirus Bio Corporation. Available: http://www.mirusbio.com/news/releases/20061031.asp.
41. Mirus Bio awarded broad RNAi patent using hydrodynamic intravascular injection. Press release from Mirus Bio Corporation. Available: http://www.mirusbio.com/news/releases/20061214.asp.
42. Mirus Bio Corporation enters into agreement with Pfizer, Inc. to evaluate RNAi delivery technology. Press release from Mirus Bio Corporation. Available: http://www.mirusbio.com/news/releases/ 20070109.asp.
43. Chen L, Woo SLC. Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA. Proc Natl Acad Sci USA 2005; 102: 15581-15586.